Vanda Pharmaceuticals ( (VNDA) ) has released its Q3 earnings. Here is a breakdown of the information Vanda Pharmaceuticals presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs, particularly in the areas of psychiatry and neurology.
In its third-quarter 2025 earnings report, Vanda Pharmaceuticals highlighted a strong commercial performance with significant growth in product sales, particularly for Fanapt, and outlined several key regulatory milestones on the horizon.
The company reported total net product sales of $56.3 million for the third quarter, marking an 18% increase year-over-year. Fanapt sales surged by 31%, driven by a 35% growth in prescriptions. Vanda is also advancing its pipeline with multiple regulatory reviews underway, including the NDAs for Bysanti and Tradipitant, and the anticipated submission of a BLA for Imsidolimab. Despite the positive sales growth, Vanda reported a net loss of $22.6 million for the quarter, attributed to increased research and development expenses and strategic investments in commercial infrastructure.
Looking ahead, Vanda Pharmaceuticals remains focused on achieving regulatory approvals for its pipeline products and strengthening its market position. The company is committed to strategic investments in its commercial infrastructure to support long-term growth and future product launches, aiming for sustained expansion and therapeutic impact in the coming years.